According to the findings of a meta-analysis of eight randomized controlled trials, GLP-1 RA and SGLT2 inhibitor combination therapy showed superior effects in reducing HbA1c, body weight, fasting and postprandial serum glucose levels, systolic blood pressure, body mass index, and LDL-C, without major safety issues, when compared with monotherapy in patients with T2DM [120]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.